Von Hippel–Lindau (VHL) Insights and Trends

• VHL disease is a rare inherited multisystem disorder characterized by the development of cysts and highly vascular tumors in multiple organs, with a significant risk of malignant transformation. Its incidence is approximately 1 in 36,000 births, and the estimated de novo mutation rate is 4.4 × 10⁻⁶ per gamete per generation.
• Individuals with VHL disease have an increased risk of developing highly vascular tumors and cysts in multiple organs. Among the associated malignancies, renal cell carcinoma (kidney cancer) is the most common, affecting approximately 40% of patients with VHL.
• Most individuals with VHL disease inherit a pathogenic VHL gene mutation from an affected parent. However, approximately 20% of cases arise from a de novo (new) mutation, meaning the genetic alteration occurs spontaneously and is not inherited from either parent.
• VHL disease has no cure; treatment focuses on early detection and management of VHL-associated tumors through regular surveillance, surgical resection, radiation therapy, targeted therapies such as tyrosine kinase inhibitors, immunotherapy, and other tumor-specific interventions aimed at preventing complications, preserving organ function, and improving long-term outcomes.
• The VHL treatment landscape is anchored by Belzutifan (WELIREG), developed by Merck, a HIF-2α inhibitor and the only approved systemic therapy for VHL-associated tumors, offering a targeted non-surgical treatment option and expanding disease management strategies for patients.
• The VHL pipeline remains sparse, with no notable or advanced-stage therapeutic candidates currently in development. As a result, WELIREG continues to be the only approved systemic therapy and the primary driver of innovation in the VHL treatment landscape.

Von Hippel–Lindau (VHL) Market Size and Forecast in the 7MM

• 2025 VHL Market Size: ~USD XX million
• 2036 Projected VHL Market Size: ~USD XX million
• VHL Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Von Hippel–Lindau (VHL) Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the VHL, historical and forecasted epidemiology, as well as the VHL market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

The Von Hippel–Lindau (VHL) market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates VHL patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in VHL and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Von Hippel–Lindau (VHL) Market

Rising Focus on Rare Disease Research and Orphan Drug Development

The VHL market is driven by growing investment in rare disease research and orphan drug development. Advances in understanding VHL biology have enabled the development of targeted therapies, particularly WELIREG, improving disease management and reducing the need for recurrent surgeries. Continued research activity and supportive regulatory incentives are expected to further support market growth.

Improved Understanding of the VHL–HIF Pathway

The VHL treatment landscape has advanced with the introduction of WELIREG, which targets the underlying VHL–HIF pathway. This precision therapy reduces reliance on repeated surgeries and improves long-term disease management, supporting continued growth of the VHL market.

Von Hippel–Lindau (VHL) Understanding

Von Hippel–Lindau (VHL) Overview and Diagnosis

VHL disease is a rare, inherited autosomal dominant disorder caused by mutations in the VHL tumor suppressor gene, leading to the development of cysts and highly vascular tumors in multiple organs, including the kidneys, central nervous system, retina, pancreas, and adrenal glands. Dysregulation of the VHL–hypoxia-inducible factor (HIF) pathway promotes abnormal cell growth and angiogenesis, increasing the risk of both benign and malignant tumors. Renal cell carcinoma is the most common malignancy associated with VHL and a major cause of disease-related morbidity and mortality. 

Diagnosis of VHL is based on characteristic clinical manifestations, family history, and confirmation through genetic testing identifying a pathogenic VHL gene mutation. Regular surveillance using imaging studies, ophthalmologic examinations, and biochemical assessments is essential for early detection of VHL-associated tumors. Timely diagnosis and continuous monitoring are critical to enabling early intervention, reducing complications, and improving long-term patient outcomes.

Further details are provided in the report.

Von Hippel–Lindau (VHL) Treatment 

Treatment of VHL primarily focuses on early detection and management of VHL-associated tumors to prevent complications, preserve organ function, and reduce disease burden. Standard management includes active surveillance, surgical resection of symptomatic or high-risk lesions, and localized interventions such as radiation therapy when appropriate. The introduction of WELIREG has provided a targeted systemic treatment option by inhibiting the HIF-2α pathway, helping to control tumor growth and reduce the need for repeated surgeries. Treatment is individualized based on tumor type, size, location, growth rate, associated symptoms, and overall patient condition.

Further details related to country-based variations are provided in the report.

Von Hippel–Lindau (VHL) Unmet Needs

The section “unmet needs of VHL” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress. 

1. Limited Availability of Approved Systemic Therapies
2. Dependence on Lifelong Surveillance and Repeated Surgical Interventions
3. Need for Durable, Multisystem Tumor Control, and others…..

Note: Comprehensive unmet needs insights in VHL and their strategic implications are provided in the full report.

Von Hippel–Lindau (VHL) Epidemiology

Key Findings from Von Hippel–Lindau (VHL) Epidemiological Analysis and Forecast 

• As per the National Cancer Institute (2021), the prevalence of VHL is estimated to be between 1 in 31,000 and 1 in 91,000 individuals.
• According to Cancer.Net (2020), it is estimated that about 1 in 30,000 people have VHL. About 10% of people with VHL do not have any family history of the condition. They have a de novo mutation, meaning a new mutation in the VHL gene not present in their parents.
• According to the National Institute for Health Research Innovation Observatory (NIHRIO) (2021), in the UK, RCCs are found in 24% to 45% of patients with VHL and are the primary inherited renal cancer. The mean age of RCC onset in VHL patients is 39 years old.
• According to the National Organization of Rare Disorders (NORD), VHL disease affects 1 in 36,000 people (10,000 cases in the United States and 200,000 cases worldwide), and 20% of patients are first-in-family or de novo cases. The mean age of onset is 26 years, and 97% of people with a VHL gene mutation have symptoms by the age of 65. VHL disease affects males and females and all ethnic groups equally, and occurs in all parts of the world.

Von Hippel–Lindau (VHL) Drug Analysis & Competitive Landscape

The VHL drug chapter provides a detailed, market-focused review of the approved therapies and the emerging pipeline. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the VHL treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the VHL therapeutics market.

Approved Therapies for Von Hippel–Lindau (VHL)

Belzutifan (WELIREG): Merck & Co.

WELIREG, developed by Merck & Co., is a first-in-class HIF-2α inhibitor and the only approved systemic therapy for Von Hippel–Lindau disease. By targeting the underlying VHL–HIF pathway, it helps control tumor growth and reduces reliance on repeated surgical interventions. Approved by the US Food and Drug Administration on August 13, 2021, WELIREG marked a significant advancement in VHL management, shifting treatment toward targeted, long-term disease control and establishing HIF-2α inhibition as a validated therapeutic approach.

Note: Detailed marketed therapies assessment will be provided in the final report.

Von Hippel–Lindau (VHL) Key Players, Market Leaders, and Emerging Companies

• Merck & Co. and others

Von Hippel–Lindau (VHL) Drug Updates 

• In February 2025, the European Commission granted conditional marketing authorization to WELIREG for adults with VHL disease-associated tumors (including RCC, CNS hemangioblastomas, and pancreatic neuroendocrine tumors) when localized procedures are unsuitable.

Von Hippel–Lindau (VHL) Market Outlook

The treatment of VHL disease is primarily focused on early detection, monitoring, and management of VHL-associated tumors to prevent complications, preserve organ function, and reduce disease burden. Management typically includes active surveillance, surgical resection, and localized interventions for symptomatic or high-risk lesions. In patients requiring systemic therapy, WELIREG is used to target the VHL–HIF pathway and control tumor growth. Treatment is individualized based on tumor type, size, location, growth rate, symptom burden, and overall patient condition.

• According to estimates, the United States accounted for the largest VHL disease market size among the 7MM in 2025 and is expected to maintain its dominance, growing at a significant CAGR during the forecast period.
• WELIREG holds the leading market share in the VHL disease treatment landscape as the only approved systemic therapy, driving adoption across eligible patients and shaping current treatment standards.

Further details will be provided in the report….

Drug Class/Insights into Leading Emerging and Marketed Therapies in VHL (2022–2036 Forecast)

HIF-2α Inhibitors: Targeted therapies such as WELIREG inhibit the HIF-2α pathway, addressing the underlying molecular mechanism of VHL disease to control tumor growth, reduce the need for repeated surgical interventions, and improve long-term disease management.

Von Hippel–Lindau (VHL) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the VHL drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

Detailed insights into emerging therapies' drug uptake are included in the report.

Market Access and Reimbursement of Von Hippel–Lindau (VHL) 

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report….

Von Hippel–Lindau (VHL) Therapies Price Scenario & Trends 

Pricing and analogue assessment of VHL therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report…

Industry Experts and Physician Views for Von Hippel–Lindau (VHL)

To keep up with VHL market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the emerging VHL therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in VHL, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights at the country level. Centers such as the Johns Hopkins University, Universitätsmedizin Berlin, Osaka University Hospital, Erasmus University Medical Center Rotterdam, etc., were contacted. Their opinion helps understand and validate current and emerging VHL therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in VHL.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. 

In the SWOT Analysis of VHL, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of VHL, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborate profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the VHL market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM VHL market. 

Report Insights

• Von Hippel–Lindau (VHL) Patient Population Forecast
• Von Hippel–Lindau (VHL) Therapeutics Market Size 
• Von Hippel–Lindau (VHL) Pipeline Analysis
• Von Hippel–Lindau (VHL) Market Size and Trends
• Von Hippel–Lindau (VHL) Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report 
• 11-Year Forecast 
• Von Hippel–Lindau (VHL) Market Outlook (North America, Europe, Asia-Pacific) 
• Patient Burden Trends (By Geography)
• Von Hippel–Lindau (VHL) Treatment Addressable Market (TAM)
• Von Hippel–Lindau (VHL) Competitive Landscape
• Von Hippel–Lindau (VHL) Major Companies Insights
• Von Hippel–Lindau (VHL) Price Trends and Analogue Assessment
• Von Hippel–Lindau (VHL) Therapies Drug Adoption/Uptake
• Von Hippel–Lindau (VHL) Therapies Peak Patient Share Analysis

Report Assessment

• Von Hippel–Lindau (VHL) Current Treatment Practices
• Von Hippel–Lindau (VHL) Unmet Needs
• Von Hippel–Lindau (VHL) Clinical Development Analysis
• Von Hippel–Lindau (VHL) Emerging Drugs Product Profiles
• Von Hippel–Lindau (VHL) Market Attractiveness
• Von Hippel–Lindau (VHL) Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

Market Insights

• What was the VHL market size, the market size by therapies, the market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of VHL?
• What are the disease risks, burdens, and unmet needs of VHL? What will be the growth opportunities across the 7MM concerning the patient population with VHL?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of VHL? What are the current guidelines for treating VHL in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the VHL market.
• Bottom-up forecasting builds from the affected population to product forecasts, delivering a robust, data-driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)- enabled report summarizes and simplifies complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data-driven decisions.